Ovarian cancer: Front-line standard treatment in 2008

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Vasey, P A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROPATHY; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; ARTICLE; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 53449087942     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn479     Document Type: Conference Paper

References (47)

1. IARC. GLOBOCAN. cancer incidence, mortality and prevalence worldwide (2002 estimates) 2002 http://www-dep.iarc.fr/.
2. Eisenhauer EL, Abu-Rustum NR, Sonada Y et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gyn Oncol 2008; 108: 276-281.
3. du Bois A, Quinn M, Thigpen T et al. 2004 Consensus statements on the management of ovarian cancer: Final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 2005; 16 (Suppl 8): Viii7-viii12.
4. Bateman JC. Chemotherapeutic management of advanced ovarian carcinoma. Med Ann Dist Columbia 1959; 28: 537-544.
5. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 1668-1674.
6. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomised trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-1487.
7. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian cancer after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-1753.
8. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol 1993; 11: 2405-2410.
9. Rowinsky EK, Dowenhower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-1014.
10. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
11. Piccart MJ, Bertelsen K, James K et al. Randomised intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results. J Natl J Inst 2000; 92: 699-708.
12. Ahern PR, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-732.
13. ICON Collaborators. ICON2: Randomized trial of single agent carboplatin against three drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet 1998; 352: 1571-1576.
14. Internatonal Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin vs standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 369: 505-515.
15. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin vs paclitaxel vs cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
16. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
17. du Bois A, Lück H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Instit 2003; 95: 1320-133.
18. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin vs paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
19. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Instit 2004; 96: 1682-1691.
20. Vasey PA, Kaye SB. Importance of dose intensity in ovarian cancer. In Gershensen DM, McGuire WP (eds): Ovarian Cancer Controversies in Management. New York: Churchill Livingstone 1998; 139-169.
21. Mobus V, Wandt H, Frickhofen N et al. Phase III trial of high dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar AIO and EBMT. J Clin Oncol 2007; 25: 4187-4193.
22. Grenman S, Wiklund T, Jalkanen J et al. A randomized phase III study comparing high-dose chemotherapy to conventionally dose chemotherapy for stage III ovarian cancer: The Finnish Ovarian Cancer (FINOVA) Study. Eur J Cancer 2006; 42: 2196-2199.
23. Vergote I, DeBrabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.
24. International Collaborative Ovarian Neoplasm I (ICON1) and European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant Chemotherapy in Ovarian Neoplasm (EORTC-ACTION). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patents with early stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
25. Trope C, Kaem J. Adjuvant chemotherapy for early stage ovarian cancer: review of the literature. J Clin Oncol 2007; 25: 2909-2920.
26. Bell J, Brady MF, Young RC et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432-439.
27. Bookman M for the Gynecologic Cancer Intergroup. GOG182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin, versus combinations with gemcitabine, pegylated liposomal doxorubicin or topotecan in patients with advanced stage epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2006; 24 (18 Suppl): 256s (Abstr 5002).
28. Markman M, Intraperitoneal antineoplastic drug delivery: Rationale and results, Lancet Oncol 2003; 4: 277-283.
29. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
30. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N EngI J Med 1996; 335: 1950-1955.
31. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1107.
32. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. no.: CD005340. DOI: 10.1002/ 14651858.CD005340.pub2.
33. Gore M, duBois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006; 24: 4528-4530.
34. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwestern Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
35. Conte PF, Favalli G, Gadducci A et al. Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. J Clin Oncol 2007; 25 (18 Suppl): 275s (Abstr 5505).
36. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: The role of angiogenesis inhibition. J Clin Oncol 2007; 25: 2894-2901.
37. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007; 25: 2902-2908.
38. Cannistra SA, Matulonis U, Penson RT et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 2006; 24 (17 Suppl): 257s (Abstr 5006).
39. Giantonio BJ, Catalano PJ, Meropol NJ et al. High dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23 (16 Suppl): 1s (Abstr 2).
40. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-5899.
41. Micha JP, Goldstein BH, Rettenmaier MA et al. A phase II study of outpatient first-line paclitaxel, carboplatin and bevacizumab for advanced stage epithelial ovarian, peritoneal and fallopian tube cancer. Int J Gynecol Cancer 2007; 17: 771-776.
42. Tew WP, Columbo N, Ray-Coquard I et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: Preliminary results of a randomised multicentre phase II study. J Clin Oncol 2007; 25 (18 Suppl): 276s.
43. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecological Oncology Group study. Clin Cancer Res 2005; 11: 5539-5548.
44. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15: 785-792.
45. Vasey PA, Gore ME, Wilson R et al. A phase IB trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008; In press.
46. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-104.
47. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.